There are actually three clinical trials evaluating the efficacy of trastuzumab (NCT04482309); PRS-343, which is a bispecific fusion protein of anti-HER2 monoclonal antibody/anti-CD137 anti-calin (NCT03330561); and PRS-343 in combination with atezolizumab (NCT03650348) in HER2-positive solid tumours, including urothelial carcinoma. The gene discussed is ERBB2; the disease is urothelial carcinoma.